Kisunla Injection, Solution
Product Images NDC 0002-9401

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Kisunla (NDC 0002-9401). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eli Lilly And Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Package Label – Kisunla 350 mg Vial (Kisunla 350mg Carton 048 00)

This is a medication label for an injection containing 350 mg of donanemab-azbt per 20 mL (17.5 mg/mL). The product is from Eli Lilly and Company in Indianapolis, USA. It is advised not to freeze or shake the product and store it at a temperature not exceeding 26°C. Dosage information is provided, and the unused portion should be discarded. The injection solution also contains other ingredients like sodium and sucrose. A dosage guide is included and dispensed with the product.*

FDA Label Image

Figure 1 (Kisunla Uspi F1 V1)

FDA Label Image

Figure 2 (Kisunla Uspi F2 V1)

This is a comparison of the LS mean change in the CDR-SB score between placebo and KISUNLA over different weeks. The data includes the number of participants in each group at various time points. The study suggests that KISUNLA may have a positive impact on the CDR-SB score compared to placebo.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.